Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.66 |
| ▸ | HPGD | P15428 | 4/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | POLB | P06746 | 2/20 | 0.66 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.66 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.66 |
| ▸ | CLK2 | P49760 | 1/20 | 0.66 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.53 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TOP1 | P11387 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Premafloxacin SCHEMBL8324081 | 0.88 | KCNH2 (0.81) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL30494409 | 0.88 | KCNH2 (0.81) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL1230382 | 0.88 | KCNH2 (0.81) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL30494408 | 0.88 | KCNH2 (0.81) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL6528754 | 0.88 | KCNH2 (0.81) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL7983357 | 0.88 | KCNH2 (0.81) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL8327470 | 0.88 | KCNH2 (0.81) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL8330342 | 0.88 | KCNH2 (0.81) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL1230600 | 0.88 | KCNH2 (0.80) | KCNH2KDM4EHPGDALDH1A1HSD17B10 | |
| Premafloxacin SCHEMBL1230581 | 0.88 | KCNH2 (0.80) | KCNH2KDM4EHPGDALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1730154-B1 | RIFAMYCIN DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE IP VENTURES L P (US) | 2012-10-17 | — | — | EP | disclosed |
| US-7247634-B2 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-7238694-B2 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE PHARMACEUTICALS, INC. (US) | 2007-07-03 | — | — | US | disclosed |
| EP-1723150-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | Cumbre Pharmaceuticals Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-11-24 | — | — | US | disclosed |
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | CUMBRE INC. (US) | 2005-09-22 | — | — | US | disclosed |
| WO-2005070941-A1 | RIFAMYCIN IMINO DERIVATIVES EFFECTIVE AGAINST DRUG-RESISTANT MICROBES | CUMBRE PHARMACEUTICALS INC. (US) | 2005-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050261262-A1 | Rifamycin derivatives effective against drug-resistant microbes | RIF1, MRPL37, AURKAIP1 | KCNH2 3101/4885KDM4E 2995/4885HPGD 1984/4885 |
| US-20050209210-A1 | Rifamycin imino derivatives effective against drug-resistant microbes | RIF1, TOP1, TOP2A | KCNH2 3651/4885KDM4E 2157/4885HPGD 1058/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.